Arizona heart centre to use CardioDx's CAD gene expression test
This article was originally published in Clinica
The Heart & Vascular Center of Arizona has become one of the first institutions to offer CardioDx's Corus CAD blood test. The "first-of-its-kind" gene expression test assesses the likelihood of obstructive coronary artery disease (CAD) in patients with stable chest pain, by measuring expression levels of 23 genes. It is intended for use with standard clinical assessments, and could be more objective and safer for patients that conventional imaging technologies, CardioDx hopes. The firm launched Corus CAD in nine US states in August after completing a validation study, and plans to expand the availability of the test in 2010. CardioDx processes samples at its CLIA-certified lab in Palo Alto, California.
You may also be interested in...
Israel is well-known as a medtech hot-spot, with a focus on academic research and strong government support helping the country punch well above its weight when it comes to innovative devices.
St Jude Medical had a heavy focus on its intravascular imaging offering at this year’s EuroPCR meeting, presenting data supporting its optical coherence tomography (OCT) technology. OCT provides intravascular images to help assess culprit lesions, which can improve stent selection and deployment, according to St Jude.
A big topic at this year’s EuroPCR, held in Paris on 19-22 May, was drug-coated balloons (DCBs). One of the leaders in the field, Medtronic, presented positive data from two studies of its IN.PACT Admiral balloon, which could support an expanded indication for the device.